Formula I Compound Combination for Cancer Treatment Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using anticancer medicaments often result in significant side effects and immunosuppression, which can lead to reduced efficacy and the development of cachexia, as these drugs also affect normal cells and induce immunosuppressive environments in tumor microenvironments.
Innovation Solution
The use of a compound of formula (I) or its pharmaceutically acceptable salt in combination with anticancer medicaments, such as topoisomerase inhibitors or platinum-based agents, to enhance cancer cell sensitivity, reduce side effects, and reverse immunosuppression, thereby attenuating cachexia symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anticancer medicaments are used to kill cancer cells, then cancer cell growth is inhibited, but normal cells are also affected causing serious side effects
Solution Approach 1:
The patent segments the therapeutic effect into two components: the anticancer medicament provides the primary cytotoxic effect, while the compound of formula (I) provides a protective effect on normal cells. This segmentation allows each component to perform its specialized function, achieving both cancer cell killing and normal cell protection simultaneously
Solution Approach 2:
The compound of formula (I) acts as an intermediary substance that mediates between the anticancer medicament and normal cells. It interferes with the interaction between the medicament and normal cells, thereby reducing the harmful effects while maintaining the therapeutic effect on cancer cells
2Reliability
If high dosage of anticancer medicaments is administered to ensure therapeutic effect, then cancer treatment efficacy is improved, but immunosuppression and cachexia symptoms worsen
Solution Approach 1:
The patent changes the dosage parameter of the anticancer medicament by introducing the compound of formula (I) as a co-administered substance. This allows the medicament to be administered at lower doses while maintaining therapeutic effect, thereby reducing immunosuppression and cachexia symptoms
Solution Approach 2:
The patent creates a composite therapeutic regimen combining the anticancer medicament with the compound of formula (I). This composite approach produces synergistic effects where the combination achieves better therapeutic outcomes at lower medicament doses, reducing harmful side effects
3Reliability
If anticancer medicaments are used to treat cancer, then tumor growth is controlled, but immunosuppressive environment is induced in tumor microenvironment
Solution Approach 1:
The patent converts the harmful immunosuppressive effect into a beneficial outcome by using the compound of formula (I) to counteract the immunosuppression induced by the anticancer medicament. This transforms the harmful immunosuppressive microenvironment into an immunocompetent environment that supports effective cancer treatment
Data Source
AI summary
A combination, comprising a first component and a second component; the first component is selected from a group composed of the following: the compound of formula (I), a pharmaceutically acceptable salt thereof, and a combination thereof, wherein A is a C1-C8 aliphatic hydrocarbon group optionally containing a carbonyl group as needed; X is H or OH; Y is O; and R1 is H or is not present, the condition being that when R1 is not present, Y and A bond to form a five-membered ring; and the second component is selected from a group composed of the following: a topoisomerase inhibitor, a microtubule assembly inhibitor, a platinum-based agent, an antimetabolite, and a combination thereof.